Context Therapeutics Inc.
CNTXDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Extended-release Onapristone
Refractory Endometrial Adenocarcinoma
Onapristone ER
Granulosa Cell Ovarian Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Extended-release Onapristone | Phase 2 | Refractory Endometrial Adenocarcinoma | - | - |
Onapristone ER | Phase 2 | Granulosa Cell Ovarian Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Context Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Context Therapeutics Inc.'s (CNTX) pipeline across Phase 2. Its lead program is Extended-release Onapristone (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Context Therapeutics Inc.'s next FDA catalyst?→
Context Therapeutics Inc.'s (CNTX) next tracked catalyst is a Earnings expected November 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CNTX biotech catalysts?→
Add CNTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Context Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.